4.3 Review

Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis

Journal

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.hbpd.2018.11.002

Keywords

Gut-liver axis; Gut microbiota; Hepatocellular carcinoma; Lipopolysaccharide; Toll-like receptor 4

Funding

  1. National Natural Science Foundation of China [81672422, 81600506]
  2. Natural Science Foundation of Zhejiang Province [LY15H160033]
  3. Zhejiang Province Health Department Program [2014KYB081, 2017KY322]
  4. Open Project in State Key Laboratory for Diagnosis and Treatment of Infectious Disease [2015KF03]
  5. Academician JieShou Li Intestinal Mucosal Barrier Fund [201208]
  6. Medical SAMP
  7. T Project of Zhejiang Province [201479797]
  8. National SAMP
  9. T Major Project of China [2018ZX10301201]

Ask authors/readers for more resources

Background: Hepatocellular carcinoma ( HCC) is one of the most common malignancies in the world. Gut microbiota has been demonstrated to play a critical role in liver inflammation, chronic fibrosis, liver cirrhosis, and HCC development through the gut-liver axis. Data sources: Recently there have been several innovative studies investigating gut microbial dysbiosismediated enhancement of HCC through the gut-liver axis. Literatures from January 1998 to January 2018 were searched in the PubMed database using the keywords gut microbiota and hepatocellular carcinoma or livercancer, and the results of experimental and clinical studies were analyzed. Results: Gut microbial dysbiosis accompanies the progression of alcoholic liver disease, non-alcoholic fatty liver disease and liver cirrhosis, and promotes HCC progression in an experimental mouse model. The immune system and key factors such as Toll-like receptor 4 are involved in the process. There is evidence for gut microbial dysbiosis in hepatitis virus-related HCC patients. Conclusions: Gut microbial dysbiosis is closely associated with hepatic inflammation disease and HCC through the gut-liver axis. With the enhanced understanding of the interactions between gut microbiota and liver through the gut-liver axis, new treatment strategies for HCC are being developed. (C) 2018 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available